Evidence map›Paper›PMID 41413594›Full record

ArticleScientific reports2025

CDC7 is a targetable regulator of advanced prostate cancer.

Alifiani B Hartono, HyeonJi Hwang, Sidharth Paparaju, Shiqin Liu, James D Brooks, Eva Corey, Tanya Stoyanova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alifiani B HartonoDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
HyeonJi HwangDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
Sidharth PaparajuDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
Shiqin LiuDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
James D BrooksCanary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, 94305, USA.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, 98105, USA.
Tanya StoyanovaDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Dr S, Los Angeles, CA, 90095, USA. tstoyanova@mednet.ucla.edu.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Testing ATAD2 as a new therapeutic target for advanced prostate cancerR01CA287669 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2024 to 2026
$2.8M
Elucidating the Role of Trop2 in Prostate CancerR37CA240822 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2020 to 2026
$2.5M
Delineate the Role of GSTP1 in Advanced Prostate CancerR01CA274978 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2023 to 2026
$1.8M
NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA274978NCI NIH HHS R01 CA287669NCI NIH HHS R37 CA240822
6 · The paper itself

Abstract

Prostate cancer is estimated to contribute to over 35,000 deaths of men residing in the United States, with the majority fatality due to metastatic disease. CDC7 is a kinase that regulates DNA replication and is found elevated during neuroendocrine transdifferentiation in lung and prostate cancer. In this study, we demonstrate that CDC7 is highly expressed in treatment-resistant prostate cancer, with even higher levels observed in treatment-resistant prostate cancer with neuroendocrine phenotype (NEPC). We further identify CDC7 as a critical regulator of prostate tumorigenesis. Downregulation of CDC7 significantly reduces prostate cancer cells growth and invasion in vitro and silencing CDC7 suppresses prostate tumor growth in vivo. Furthermore, we demonstrate that the inhibition of CDC7 using TAK-931, a selective CDC7 inhibitor, significantly reduces the proliferation, migration, and invasion of aggressive prostate cancer cells. TAK-931 treated prostate cancer cells exhibit an abnormal cell cycle profile, suggesting that CDC7 inhibition induces replication stress and promotes apoptosis. Collectively, our findings demonstrate that CDC7 is a regulator of tumor progression in prostate cancer and represents new therapeutic target in advanced prostate cancer.

Indexed as

Cell Cycle ProteinsProstatic NeoplasmsProtein Serine-Threonine KinasesAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiceCDC7 protein, humanCell Cycle ProteinsProtein Serine-Threonine Kinases

Identifiers

PMID41413594
PMCPMC12770614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.